Materials and methods for treatment of plaquing disease

• US 5,753,624 A
• Filed: 08/08/1996
• Issued: 05/19/1998
• Est. Priority Date: 04/27/1990
• Status: Expired due to Fees

• Current Assignee: Milkhaus Laboratory, Inc.
• Original Assignee: Milkhaus Laboratory, Inc.
• Inventors: Kline, Ellis L., McMichael, John
• Primary Examiner(s): Tsang, Cecilia J.
• Assistant Examiner(s): TOUZEAU, LYNN
• Application Number:
  US08/689,528
• Time in Patent Office: 649 Days
• Field of Search: 514/12, 514/21, 424/206.1
• US Class Current: 514/17.8
• CPC Class Codes: A61K 2039/541 Mucosal route
• CPC Class Codes: A61K 2039/542 oral/gastrointestinal
• CPC Class Codes: A61K 2039/70 Multivalent vaccine
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/145 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: A61K 39/20 Rubella virus
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C12N 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Methods and compositions are provided for alleviation of disease states involving plaque formation, such as are manifested in Alzheimer'"'"'s Disease and other amyloid disorders, and arteriosclerotic disease. Methods for the treatment of herpes virus infections by administration of thimerosal are further provided by the invention.

Claims

1. A method for alleviating the symptoms of disease states associated with amyloid plaque formation selected from the group consisting of Alzheimer'"'"'s disease or Parkinson'"'"'s disease comprising the step of administering to a patient in need thereof an effective amount of amyloid protein.

2. The method of claim 1 wherein the amyloid protein is an amyloid beta protein.

3. The method of claim 1 wherein the amyloid protein is a fragment comprising the first 28 amino acid residues of the amyloid beta protein.

4. The method of claim 1 wherein from about 10^-10 to about 10^-2 mg of amyloid protein is administered per dose.

5. The method of claim 1 wherein from about 10^-5 to about 10^-3 mg of amyloid protein is administered per dose.

6. The method of claim 1 wherein the disease state is Alzheimer'"'"'s Disease.

7. The method of claim 1 wherein the disease state is Parkinson'"'"'s Disease.

8. The method of claim 1 wherein said effective amount of amyloid protein or a therapeutically-active fragment thereof is administered to a patient in need thereof in a composition also comprising thimerosal.

9. The method of claim 8, wherein said composition comprises from about 10^-10 to about 10^-2 mg of amyloid protein and from about 0.05 μ

g to about 500 μ

g thimerosal.

10. The method of claim 9 wherein said composition is administered to a patient in an amount of about 0.05 cc of the composition.

11. A pharmaceutical composition for treatment of disease states associated with abnormal accumulation or molecular organization of amyloid protein or amyloid plaques selected from the group consisting of Alzheimer'"'"'s disease or Parkinson'"'"'s disease which comprises amyloid protein or a therapeutically active fragment thereof in an amount effective to alleviate one or more symptoms of said disease state and a suitable carrier.

12. The pharmaceutical composition of claim 11 wherein the amyloid protein is amyloid beta protein.

13. The pharmaceutical composition of claim 11 wherein the amyloid protein is a fragment comprising the first 28 amino acid residues of the amyloid beta protein.

14. The pharmaceutical composition of claim 11 in the form of a single dosage unit which comprises from about 10^-10 to about 10^-2 mg of amyloid beta protein in association with pharmaceutically acceptable excipients.

15. The pharmaceutical composition of claim 11 further comprising an effective amount of thimerosal.

16. The pharmaceutical composition of claim 14;

wherein said composition comprises from about 10^-10 to about 10^-2 mg of amyloid protein and from about 0.05 μ

g to about 500 μ

g of thimerosal.